BEIJING, Nov. 4 /Xinhua-PRNewswire-FirstCall/ -- Lotus Pharmaceuticals,
Inc. (OTC Bulletin Board: LTUS) ("Lotus" or the "Company"), a
pharmaceutical company in the People's Republic of China ("PRC"), today
announced that it will present at the upcoming Rodman & Renshaw Global
Investment Conference taking place from November 10 to 12, 2008 in New York
The date, time and location of Lotus Pharmaceuticals' presentation at the conference are:
Date: Tuesday, November 11, 2008
Time: 12:25 P.M. EST
Venue: Henry Salon, 5th Floor
The New York Palace Hotel
455 Madison Avenue
New York, NY 10022
This three day conference will feature presentations from more than 250 companies in the healthcare, steel, metals and mining and energy industries, with an "Asia & Growth" track. The Company's Chief Financial Officer will present at the conference. For more information about the conference, please view http://www.rodmanandrenshaw.com or E-mail firstname.lastname@example.org
About Lotus Pharmaceuticals, Inc.
Lotus Pharmaceuticals, Inc. controls and operates Liangfang Pharmaceutical Company, Ltd. ("Liang Fang") and En Ze Jia Shi Pharmaceutical Company, Ltd. ("En Ze"), two pharmaceutical companies located in Beijing, China. Together, Liang Fang and En Ze form an operating company (together, "Lotus East"). Lotus East engages in the development of new drugs, drug manufacturing, and the marketing and sales of pharmaceuticals. Lotus East has advanced pharmaceutical production equipment with which it produces a portfolio of pharmaceutical products, and meets National GMP. Lotus East has a number of highly skilled scientists, 2,000 square meters of office space and a 1,000 square meter warehouse. It operates ten retail pharmacies in the Beijing area.
Safe Harbor Statement
This press release contains "forward-looking statements" within the
meaning of the "safe-harbor" provisions of the Private Securities
Litigation Reform Act of 1995. Such statements involve known and unknown
risks, uncertainties and other factors that could cause the actual results
of the Company to differ materially from the results expressed or implied
by such statements, including changes from anticipated levels of sales,
future national or regional economic and competitive and regulatory
conditions, changes in relationships with customers, access to capital,
difficulties in developing and marketing new products, marketing existing
products, customer acceptance of existing and new products, and other
factors. Additional information regarding risks can be found in the
Company's Annual Report on Form 10K filed with the SEC. Accordingly,
although the Company believes that the expectations reflected in such
forward-looking statements are reasonable, there can be no assurance that
such expectations will prove to be correct. The Company has no obligation
to update the forward-looking information contained in this press release.
For more information, please contact:
Lotus Pharmaceuticals, Inc.
Mr. Adam Wasserman, CFO
CCG Investor Relations Inc.
Mr. Crocker Coulson, President
Phone: +1-646-213-1915 (New York)
|SOURCE Lotus Pharmaceuticals, Inc.|
Copyright©2008 PR Newswire.
All rights reserved